🇺🇸 FDA
Pipeline program

Teriflunomide

MS200527_0082

Phase 3 small_molecule terminated

Quick answer

Teriflunomide for Relapsing Multiple Sclerosis is a Phase 3 program (small_molecule) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck KGaA, Darmstadt, Germany
Indication
Relapsing Multiple Sclerosis
Phase
Phase 3
Modality
small_molecule
Status
terminated

Clinical trials